Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …

Aim The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical
outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure …

Aims Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and
heart failure (HF) admissions in patients with chronic HF. However, safety and clinical …

Background: Effective diuretic regimens using loop diuretics in patients with acute
decompensated heart failure are often limited by the development of worsening kidney …

Background: Sodium-glucose cotransporter-2 inhibitors improve heart failure–related
outcomes. The mechanisms underlying these benefits are not well understood, but diuretic …

Aims Treatment with sodium–glucose co‐transporter 2 (SGLT2) inhibitors improves
outcomes in patients with chronic heart failure (HF) with reduced ejection fraction. There is …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …

Background: Empagliflozin reduces the risk of hospitalization for heart failure in patients with
type 2 diabetes and cardiovascular disease. We sought to elucidate the effect of …

Background: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure–
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …

Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …